FAST LIGAND FOR PROTECTION OF TRANSPLANTED B ISLET CELLS
用于保护移植的 B 胰岛细胞的快速配体
基本信息
- 批准号:2536604
- 负责人:
- 金额:$ 9.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-04-01 至 1999-09-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION: (Adapted from the Applicant's Abstract): The goal of the
research proposed in this application is the bioengineering of
allogeneic and xenogeneic beta islet cells that would be accepted for
implantation without encapsulation in a manufactured biomaterial.
Recent studies indicate that expression of Fas ligand (FasL) can induce
tolerance by stimulation of apoptosis in Fas+ macrophages and activated
T cells. Specific Aims of the Phase I research are as follows: (1)
Determine if there is increased survival of islets from lpr mice in gld
mice compared to gld into lpr mice. (2) Determine if beta islet cells
from rat insulin promoter-FasL transgenic mice exhibit prolonged graft
survival. (3) Determined if prolonged allograft survival will occur
with grafts of mouse and human islets infected with FasL adenovirus.
These studies are expected to provide the basis for Phase II work to
develop transgenic pigs with human FasL under the control of the insulin
promoter for beta islet cell transplantation. The commercial
application would be the readily available supply of islet cells with
stable Fas L expression for transplantation as an artificial pancreas
in patients with diabetes mellitus.
PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE
描述:(改编自申请人摘要):本项目的目标
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John D Mountz其他文献
John D Mountz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John D Mountz', 18)}}的其他基金
Cytokine-mediated B-cell development in lupus
细胞因子介导的狼疮 B 细胞发育
- 批准号:
10584137 - 财政年份:2023
- 资助金额:
$ 9.99万 - 项目类别:
B-cell innate and adaptive protective immunity to SARS-CoV-2
B 细胞对 SARS-CoV-2 的先天性和适应性保护性免疫
- 批准号:
10778521 - 财政年份:2021
- 资助金额:
$ 9.99万 - 项目类别:
B-cell innate and adaptive protective immunity to SARS-CoV-2
B 细胞对 SARS-CoV-2 的先天性和适应性保护性免疫
- 批准号:
10154041 - 财政年份:2021
- 资助金额:
$ 9.99万 - 项目类别:
B-cell innate and adaptive protective immunity to SARS-CoV-2
B 细胞对 SARS-CoV-2 的先天性和适应性保护性免疫
- 批准号:
10341174 - 财政年份:2021
- 资助金额:
$ 9.99万 - 项目类别:
B cell intrinsic interferon-beta regulates autoreactive B cell development
B 细胞内在干扰素-β 调节自身反应性 B 细胞发育
- 批准号:
10326335 - 财政年份:2018
- 资助金额:
$ 9.99万 - 项目类别:
Interferon Beta Initiated Development of Immunogenic T1 B cells in Lupus
干扰素 Beta 启动狼疮中免疫原性 T1 B 细胞的发育
- 批准号:
10046270 - 财政年份:2017
- 资助金额:
$ 9.99万 - 项目类别:
Interferon Beta Initiated Development of Immunogenic T1 B cells in Lupus
干扰素 Beta 启动狼疮中免疫原性 T1 B 细胞的发育
- 批准号:
10477180 - 财政年份:2017
- 资助金额:
$ 9.99万 - 项目类别:
Training Program in Rheumatic and Musculoskeletal Diseases Research
风湿病和肌肉骨骼疾病研究培训计划
- 批准号:
10628089 - 财政年份:2016
- 资助金额:
$ 9.99万 - 项目类别:
Role of ST6Gal I-Mediated Receptor Sialylation in Autoimmune Disease
ST6Gal I 介导的受体唾液酸化在自身免疫性疾病中的作用
- 批准号:
8309520 - 财政年份:2011
- 资助金额:
$ 9.99万 - 项目类别: